News & Updates from the National Brain Tumor Society
Tackling Clinical Trial Design From All Angles
Clinical trials are the last, crucial step for getting brain tumor treatments approved for patient use. Unfortunately, the success rate is low – only 34% of potential therapies make it through critical phase III trials. National Brain Tumor Society is committed to driving progress within the clinical trials process to increase the availability of new treatments.
Our Clinical Trial Endpoints Initiative is seeking to simplify earlier-stage trials, and thus accelerate the pace of potential brain tumor drug approvals. At the same time, we're exploring how to apply the concept of an "adaptive clinical trial" design to brain tumors. Adaptive clinical trials, particularly the I-SPY 2 model that has been delivering promising early results in the breast cancer field, offer hope to improve later-stage clinical trials.
Dr. Donald A. Berry, PhD, a leading biostatistician from MD Anderson Cancer Center, and one of the designers of the I-SPY 2 trial, has been supporting the National Brain Tumor Society in these early discussions. Dr. Berry notes that the advantages of the I-SPY 2 model include "the ability to stop assigning a therapy to... patients for whom it is offering no benefit... The design is great for patients in the trial, while at the same time accelerating drug development and making it more accurate."
We will share more insight into this topic in the coming months. In the meantime, we encourage you to explore the I-SPY 2 trial website to learn more.
From the Blog
March 27, 2014
Project Impact Gets to Work: Removing Barriers to Pediatric Cancer Treatments
The choice of when to push change in a broken system, "depends largely on timing, opportunity, and the leverage of the people initiating the change," according to popular theories in system change. Moreover, to achieve systems change leaders must, "bring people addressing parts of the problem around the same table," and by "...inviting new people [...]
Reasons to Run: Brooke Howitt E., M.D. Competes In The Boston Marathon to Fight Brain Tumors
On Patriots Day, April 21, 2014, runners from across the globe will compete in the annual Boston Marathon, one of the most renowned running competitions in the world. This year, the National Brain Tumor Society was fortunate enough to receive a number from the town of Newton, and we are excited to provide our number [...]
National Brain Tumor Society is fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and anyone who will be diagnosed tomorrow. This means effecting change in the system at all levels.